MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

MDT

94.83

-0.27%↓

VEEV

293.46

-1.25%↓

A

138.64

+8.17%↑

HQY

90.28

-4.74%↓

PHR.US

22.45

-4.59%↓

Search

Akebia Therapeutics Inc

Fermé

SecteurSoins de santé

2.68 -1.47

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.67

Max

2.73

Chiffres clés

By Trading Economics

Revenu

-5.9M

247K

Ventes

5.1M

62M

Marge bénéficiaire

0.395

Employés

181

EBITDA

-6.1M

7.4M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+156.41% upside

Dividendes

By Dow Jones

Prochains Résultats

6 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-162M

726M

Ouverture précédente

4.15

Clôture précédente

2.68

Sentiment de l'Actualité

By Acuity

94%

6%

356 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Akebia Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 sept. 2025, 23:56 UTC

Acquisitions, Fusions, Rachats

Eagers Automotive Enters Canada Via A$1 Billion Investment in CanadaOne Auto

30 sept. 2025, 23:43 UTC

Actions en Tendance

Stocks to Watch: GEO Group, Lithium Americas, Nike

30 sept. 2025, 23:12 UTC

Résultats

Nike 1Q Sales Rise But Warns of Continued Weakness in China -- 2nd Update

30 sept. 2025, 22:48 UTC

Acquisitions, Fusions, Rachats

Lifeway Foods, Danone Agree to Stay Litigation -- Update

30 sept. 2025, 22:01 UTC

Acquisitions, Fusions, Rachats

Lifeway Foods, Danone Agree to Stay Litigation

30 sept. 2025, 21:17 UTC

Résultats

Nike 1Q Sales Rise as Turnaround Progresses -- Update

30 sept. 2025, 20:47 UTC

Résultats

Nike 1Q Sales Rise as Turnaround Progresses

30 sept. 2025, 23:45 UTC

Market Talk

Nikkei May Trade in a Range Amid Uncertainty Over U.S. Govt Shutdown -- Market Talk

30 sept. 2025, 23:45 UTC

Market Talk

Gold Edges Higher Amid Ongoing U.S. Government Shutdown Risks -- Market Talk

30 sept. 2025, 23:26 UTC

Acquisitions, Fusions, Rachats

Eagers Automotive to Issue Shares at A$21.00 Each Via Entitlement Offer

30 sept. 2025, 23:26 UTC

Acquisitions, Fusions, Rachats

Eagers Automotive to Launch Partly Underwritten A$452 Million Entitlement Offer

30 sept. 2025, 23:25 UTC

Acquisitions, Fusions, Rachats

Eagers Automotive Says Equity Raising Includes A$50 Million Placement to Mitsubishi

30 sept. 2025, 23:24 UTC

Acquisitions, Fusions, Rachats

Eagers Automotive Says Transaction With Mitsubishi Corp Worth A$70 Million

30 sept. 2025, 23:24 UTC

Acquisitions, Fusions, Rachats

Eagers Automotive Says Mitsubishi Corp to Acquire 20% of easyauto123

30 sept. 2025, 22:54 UTC

Market Talk

Timing of CSL's Change of CFO Queried by Bull -- Market Talk

30 sept. 2025, 22:38 UTC

Résultats

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30 sept. 2025, 22:32 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30 sept. 2025, 22:32 UTC

Market Talk

Commonwealth Bank Pushes Out Next RBA Rate Cut to February -- Market Talk

30 sept. 2025, 22:03 UTC

Acquisitions, Fusions, Rachats

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30 sept. 2025, 21:32 UTC

Acquisitions, Fusions, Rachats

Berkshire's Potential Deal for Occidental Chemical Business Would Be a Win for Buffett -- Barrons.com

30 sept. 2025, 21:02 UTC

Résultats

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Inches Higher. -- Barrons.com

30 sept. 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

30 sept. 2025, 20:50 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

30 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 sept. 2025, 20:28 UTC

Résultats

Nike Tops Earnings Estimates and Posts Surprise Revenue Increase. The Stock Rises. -- Barrons.com

30 sept. 2025, 20:22 UTC

Résultats

Nike 1Q North America Revenue $5.02B >NKE

30 sept. 2025, 20:22 UTC

Résultats

Nike 1Q Asia Pacific & Latin America Revenue $1.49B >NKE

30 sept. 2025, 20:22 UTC

Résultats

Nike 1Q Europe, Middle East & Africa Revenue $3.33B >NKE

30 sept. 2025, 20:22 UTC

Résultats

Nike 1Q Greater China Revenue $1.51B >NKE

30 sept. 2025, 20:19 UTC

Résultats

Nike Cash and Equivalents and Short-Term Investments Were $8.6 B as of Aug 31 >NKE

Comparaison

Variation de prix

Akebia Therapeutics Inc prévision

Objectif de Prix

By TipRanks

156.41% hausse

Prévisions sur 12 Mois

Moyen 7 USD  156.41%

Haut 8 USD

Bas 6 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

3

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

2.345 / N/ASupport & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

356 / 371Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat